

1 **Elevated 11-oxygenated androgens are not a major contributor to HPG-axis disturbances**
2 **in adults with congenital adrenal hyperplasia due to 21-hydroxylase deficiency**

3 Matthias K. Auer¹, Luisa Paizoni¹, Meike Neuner¹, Christian Lottspeich¹, Heinrich Schmidt², Martin
4 Bidlingmaier¹, James Hawley³, Brian Keevil³, Nicole Reisch¹

5 ¹Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München, Munich,
6 Germany

7 ²Department of Pediatric Endocrinology, Dr. von Haunersches Children's Hospital, Klinikum der
8 Universität München, LMU München, Munich, Germany

9 ³Department of Clinical Biochemistry, Manchester University Foundation NHS Trust, Manchester
10 Academic Health Sciences Centre, Southmoor Rd, Manchester, UK

11

12 **Corresponding author:**

13 Nicole Reisch

14 Medizinische Klinik and Poliklinik IV, Klinikum der Universität München

15 Ziemssenstr. 1

16 80336 München

17 Germany

18 Email: Nicole.reisch@med.uni-muenchen.de

19

20 **Declaration of interest**

21

22 All authors have declared that no conflict of interest exists

23

24

25

26

27

28

29 **Highlights**

30

31 • The 11-oxygenated androgens 11-ketotestosterone and 11 β -hydroxyandrostenedione are
32 significantly elevated in men with CAH with hypogonadotropic hypogonadism and women with
33 amenorrhea.

34 • Elevated 17-OHP levels in male patients and elevated testosterone levels in female patients are
35 however the dominant predictor of HPG-axis disturbances.

36 • 11-oxygenated androgens are not predictive for testicular adrenal rest tumors in men with CAH

37 • 11-ketotestosterone and 11 β -hydroxyandrostenedione levels do not seem to be influenced by
38 intake of oral contraceptives.

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54 **Abstract**

55 **Context**

56 Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in patients with
57 classic congenital adrenal hyperplasia (CAH). 11-oxygenated androgens have been suggested to play
58 a role in this context.

59 **Design**

60 Cross-sectional single center study including 89 patients (N=42 men, N=55 women) with classic CAH.

61 **Main Outcome Measures**

62 Independent predictors for hypogonadism in men and secondary amenorrhea in women with CAH with
63 a special focus on 11-ketotestosterone (11KT) and 11 β -hydroxyandrostenedione (11OHA4).

64 **Results**

65 Hypogonadotropic hypogonadism was present in 23% of men and 61% of those women currently not
66 on contraceptives suffered from irregular menstrual cycles or amenorrhea. Testicular adrenal rest
67 tumor (TART) was documented in 28% of men. While 11KT (3.5x) and 11OHA4 (5.7x) among other
68 adrenal steroids were significantly elevated in men with hypogonadism, in stepwise logistic regression,
69 the only significant independent predictor for hypogonadism were elevated 17-OHP levels (B = 0.006;
70 p = 0.039). Although 11KT (5.2x) and 11OHA4 (3.7x) levels were also significantly higher in women
71 with amenorrhea in comparison to those with a regular cycle, the only significant predictor for
72 amenorrhea were elevated total testosterone levels (B = 1.806; p = 0.040). 11-oxygenated androgens
73 were not different in those with TART and those without. Of note, there were no significant differences
74 in 11OHA4 or 11KT between those with a regular cycle and those currently on hormonal
75 contraceptives.

76 **Conclusions**

77 11-oxygenated androgens do not seem to add additional information for explaining menstrual
78 disturbances and hypogonadism in patients with CAH in comparison to established marker of disease
79 control.

80

81 **Keywords**

82 Congenital adrenal hyperplasia, hypogonadism, menstrual cycle, 11-ketotestosterone, 11-oxygenated
83 androgens

84

85 **Abbreviations**

86	11KT	11-ketotestosterone
87	11OHA4	11 β -hydroxyandrostenedione
88	17-OHP	17 α -hydroxyprogesterone
89	ACTH	Adrenocorticotrophic hormone
90	AR	Androgen receptor
91	CAH	Congenital adrenal hyperplasia
92	CPA	Cyproterone acetate
93	DHEAS	Dehydroepiandrosterone sulfate
94	ER	Estrogen receptor
95	FC	Fludrocortisone
96	FSH	Follicle-stimulating hormone
97	GC	Glucocorticoid(s)
98	GnRH	Gonadotropin releasing hormone
99	HC	Hydrocortisone
100	HPG	Hypothalamus-pituitary-gonadal
101	LH	Luteinizing hormone
102	PR	Progesterone receptor
103	SERM	Selective estrogen receptor modulator
104	SHBG	Sex hormone binding globulin
105	SV	Simply virilizing
106	SW	Salt-wasting
107	TART	Testicular adrenal rest tumor

108

109 **Acknowledgments**

110 We thank all participants for taking part in this study

111
112 **Funding**

113
114 This work was supported by the IFCAH grant 2013 to NR and by the Deutsche
115 Forschungsgemeinschaft (Heisenberg Professorship 325768017 to NR and Projektnummer:
116 314061271-TRR205 to NR). The authors declare no competing interests.

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134 **1. Introduction**

135 Congenital adrenal hyperplasia (CAH) encompasses a group of hereditary autosomal recessive
136 disorders that are characterized by mutations in key enzymes of cortisol synthesis. Among these,
137 patients affected by mutations in the 21-alpha hydroxylase gene are the largest entity (1). Depending
138 on the severity of the underlying mutation, patients are either suffering from isolated glucocorticoid-
139 (simply virilizing form= SV) or additional mineralocorticoid-deficiency, when less than 1-2% of
140 enzymatic activity is retained (salt-wasting = SW). Glucocorticoid deficiency in turn results in ACTH
141 overstimulation due to the loss of hypothalamo-pituitary negative feedback which subsequently drives
142 excessive adrenal androgen production (2).

143 Hypothalamus-pituitary-gonadal (HPG)-axis disturbances are a common phenomenon in CAH patients
144 of both sexes. In particular in women in the fertile age, menstrual disturbances occur in up to 30% (3-
145 5). The most obvious mechanism for this finding is the inherent extra-gonadal androgen and
146 progesterone production in CAH. Correspondingly, menstrual cycle disturbances in female patients
147 with CAH have been associated with poor treatment control as indicated by increased 17-OHP,
148 testosterone, progesterone and androstenedione levels (6). In line, a recent study from the DSD-life
149 cohort demonstrated that an androstenedione/testosterone ratio ≥ 1 , indicating excessive adrenal
150 testosterone production, is a strong predictor of sub-normal testosterone levels in men with CAH (7).
151 Most of these patients correspondingly present with low or inadequately low gonadotropin levels
152 indicating hypogonadotropic hypogonadism, while some patients also show signs of primary testicular
153 damage mainly due to testicular adrenal rest tumor (TART) formation (7-9)

154 However, HPG-axis disturbances can also be found in patients who are regarded well controlled
155 based on the aforementioned treatment markers (4,10). The exact culprit for HPG disturbances is
156 therefore not always clear, as all major steroids, namely testosterone, estradiol and progesterone are
157 important parts of the HPG feedback loop (11).

158 In recent years, a further class of adrenal-derived androgens has come into focus in the context of
159 CAH. These are 11-oxygenated 19-carbon androgens, in particular 11-ketotestosterone (11KT) and
160 11 β -hydroxyandrostenedione (11OHA4). Androstenedione can be converted to 11OHA4 by 11 β -
161 hydroxylase, then to 11-ketoandrostenedione through the action of 11 β -hydroxysteroid
162 dehydrogenase type 2 and finally to 11KT (12,13). It has been demonstrated that 11KT and its

163 derivate 11KT-dihydrotestosterone act at the androgen receptor with equal potency to the classic
164 testosterone and dihydrotestosterone (DHT) (14). Correspondingly, it has been shown that these
165 steroids are significantly elevated in patients with classic CAH (15). While it has been suggested that
166 elevated 11KT levels might contribute to HPG-suppression at the hypothalamic and pituitary level,
167 their clinical relevance has still to be determined (16). Although testosterone exerts direct negative
168 effects at the hypothalamic levels via AR binding (17,18), estradiol seems to be the dominant
169 suppressor in this context (19). As 11KT cannot be directly aromatized questions a dominant role in
170 HPG suppression in this context (14).

171 In the present study, we were therefore interested if 11-oxygenated androgens, in particular 11-KT
172 would add information on HPG-axis disturbances in adult patients with CAH due to 21-hydroxylase
173 deficiency in addition to established markers of disease control.

174 In detail, we hypothesized that 11KT would be higher in men with hypogonadotropic hypogonadism
175 than in those with eugonadism, that 11OHA4 would be higher in males with TART than in those
176 without and that 11KT and 11OHA4 would be higher in women with menstrual irregularities in contrast
177 to those with eumenorrhoea. In an exploratory analysis we were further interested if 11KT and
178 11OHA4 would differ between women with a regular cycle and those on oral contraceptive therapy to
179 estimate if these potential covariates should be accounted for in the clinical context if our main
180 hypotheses would hold true.

181 **2. Material and Methods**

182 **Subjects**

183 We included 89 patients (N=42 men, N=55 women) of whom 58 were suffering from SW and 31 of the
184 SV form of CAH. All patients were seen at the outpatient clinic of the Medizinische Klinik IV, Klinikum
185 der Universität München, LMU Munich. All patients were directly approached during a regular visit in
186 the outpatient clinic. The recruitment period was from January 2012 to January 2014. The local ethics
187 committee of the Ludwig-Maximilians-Universität München approved the study protocol. All
188 participants provided their written informed consent.

189

190 **Testicular ultrasound**

191 Testicular ultrasound was performed in the Department of Endocrinology in the University Hospital
192 Munich by a trained sonographer (Siemens Acuson S2000). Testicular ultrasound was performed
193 documenting testicular masses. Greyscale and color Doppler ultrasonography were obtained in the
194 longitudinal and transverse planes using a 15MHz transducer. Data on TART was missing in seven
195 men.

196

197 **Hormone assays and hormonal control**

198 Blood was drawn in fasting patients in the morning between 8 and 10 a.m., roughly 2 hours after the
199 intake of the morning medication of participants. Concentrations of adrenocorticotrophic hormone
200 (ACTH), sex hormone binding globulin (SHBG) and DHEAS were determined using the Liaison
201 chemiluminescence immunoassays (DiaSorin, Sallugia, Italy).

202 Total testosterone, 17-OHP, androstenedione, 11-KT and 11OHA4 were quantified by LC-MS/MS.
203 Steroid extraction and quantitation was carried out as previously described (20).

204 Daily doses of glucocorticoids and mineralocorticoids were evaluated. Equal hydrocortisone doses
205 were calculated according to their suggested androgen-suppressive capacity (hydrocortisone=1,
206 prednisolone=4, dexamethasone=70) and adjusted to the patients' body surface area (2). In men,
207 hypogonadism was defined as having a low testosterone level <12nmol/l (21)(39). Hypogonadotropic
208 hypogonadism was defined as having low testosterone levels with inappropriately normal or low
209 LH/FSH. Secondary amenorrhea was defined as not having had a spontaneous menstrual bleeding
210 during the last six months prior to study inclusion, while irregular cycles were defined as having as
211 cycle length that was less than 21 or more than 35 days (22).

212

213 **Statistical analysis**

214 Statistical analysis was performed using PASW Statistics (formerly SPSS) Version 22.0 for Windows.
215 Sample characteristics were compared using χ^2 tests for categorical variables and the Mann-Whitney
216 U test for continuous variables.

217 Spearman correlation was performed for univariate correlations. Partial regression analyses with LH
218 and FSH as a dependent variable and potential influential factors as independent variables were
219 performed adjusted for age and BMI. Separate multivariate regression analyses were used to identify
220 independent contributors for hypogonadism in men and secondary amenorrhea in women. Due to the
221 strong correlation among most steroid measures, variables were mean centered before addition to the

222 model. A two-block linear regression analysis was carried out to assess the contribution of different
223 variables. Block 1 included age and BMI using a forced entry method. In Block 2, we added CAH-
224 specific covariates using forward stepwise regression analysis. A two-sided P value of <0.05 was
225 considered statistically significant.

226

227 **3. Results**

228

229 **General characteristics**

230 The median age of the cohort was 28 years (range 18-61). The median GC equivalence dosage was
231 16.0 mg/m²/d for men and 14.6 mg/m²/d for women. According to the expected (residual) enzymatic
232 activity, thirteen (21.0% of whom data was available) patients were assigned to genotype group 0, 21
233 (33.9%) to genotype group A, 24 (38.7%) to genotype group B and four (6.5%) patients to genotype
234 group C (23).

235 Of those investigated, TART was present in eleven patients (28.2%). 23% presented with
236 hypogonadotropic hypogonadism. There were no men with primary hypogonadism.

237 Thirty seven percent of women were currently receiving hormonal contraceptive therapy. From those
238 without oral contraception and in premenopausal age, 38.7% had a regular cycle while 25.8% had
239 irregular menses and 35.5% were amenorrhoeic. Three women were postmenopausal (6%). At study
240 inclusion, of those with a regular cycle, 75% were in the follicular and 25% in the luteal phase of the
241 cycle (Table 1).

242 **Table 1 General characteristics**

		Men		Women		
		N (39)	%	N (50)	%	p
Mutation						
Mutation group	0	8	21	5	10	0.293
	A	12	31	9	18	
	B	8	21	16	32	
	C	2	5	2	4	
	Unknown	9	23	18	36	
Simply virilizing		12	31	19	38	
Salt wasting		27	69	32	64	0.477

TART	Yes	11	28.2	NA	NA		
	unilateral	3		NA	NA		
	bilateral	7		NA	NA		
	No	21	53.8	NA	NA		
	Missing	7	17.9	NA	NA		
Hypogonadism			0				NA
	Eugonadism	30	77	NA	NA		
	Sec. hypogonadismus	9	23	NA	NA		
	Primary hypogonadism	0	0	NA	NA		
Cycle	Oral contraception	NA	NA	16	32		NA
	Regular cycle	NA	NA	12	24	38.7*	
	Follicular	NA	NA	9	12	75%**	
	Luteal	NA	NA	3	8	25%**	
	Irregular menses	NA	NA	8	16	25.8*	
	Secondary amenorrhea	NA	NA	11	22	35.5*	
	Postmenopausal	NA	NA	3	6		
			0		0		
GC	None	0	0	2	4		0.359
	HC	18	46	19	38		
	Predniso-ne/-lone	16	41	24	48		
	Dexa	4	10	3	6		
	HC + Dexa	0	0	3	6		
	Predniso-ne/-lone +Dexa	1	3	0	0		
			Median		Median		
HC Equivalence-dosage (mg/m ²)		14.6		16.0			0.143

243 *Man-Whitney U, X2 test*

244 **Of those not on contraception*

245 ***of those with regular cycle*

246 *NA not applicable*

247 *TART: testicular adrenal rest tumor*

248 *HC: hydrocortisone*

249 *GC: glucocorticoid*

250 *Dexa: Dexamethasone*

251 *TART: Testicular adrenal rest tumor*

252

253 There were no significant differences in androstenedione,17-OHP,11KT and 11OHA4 levels between

254 men and women. (Table 2).

255

256

257 **Table 2 Anthropometric measures and hormone values**

	Men			Women			p
	Median	Percentiles		Median	Percentiles		
		25	75		25	75	
Age	28.0	24.0	40.0	29.0	24.0	38.0	0.990
BMI (kg/m ²)	26.0	22.7	29.9	26.8	22.3	30.8	ND
Waist (cm)	95.0	81.3	100.8	78.0	70.0	92.0	ND
Body fat (%)	25.6	13.1	25.7	34.3	18.5	33.2	ND
Lean mass (%)	57.1	52.5	63.1	44.4	40.1	48.8	ND
LH (U/l)	3.0	1.8	4.7	3.4	0.9	5.7	ND
FSH (U/l)	5.0	2.8	7.2	4.6	2.8	6.9	ND
ACTH (pg/ml)	11.0	6.0	55.0	10.0	4.0	29.0	0.219
Testosterone (nmol/l)	13.0	10.9	16.7	0.5	0.2	1.5	ND
Androstenedione (nmol/l)	3.6	1.1	8.2	2.0	0.9	6.0	0.155
17-OHP (nmol/l)	23.3	5.2	153.6	14.0	2.8	64.5	0.125
11KT (nmol/l)	1.2	0.3	2.4	0.6	0.2	2.4	0.335
11OHA4 (nmol/l)	2.0	0.3	8.0	1.3	0.3	5.5	0.550
DHEAS (µg/ml)	0.3	0.2	0.5	0.0	0.0	0.2	ND
SHBG (nmol/l)	33.5	24.1	39.1	57.8	39.2	145.1	ND
A/T-ratio	0.30	0.1	0.7	3.7	3.5	4.8	ND
11KT/T-ratio	0.1	0.02	0.24	1.2	1.0	1.7	ND
FAI (%)	12.4	9.0	17.2	0.2	0.1	0.8	ND
HOMA-IR	1.6	1.1	2.0	2.2	1.0	3.4	0.190

258 *Mann-Whitney U*

259 *ND not determined*

260 *FAI: free androgen index*

261 *11OHA4: 11-β hydroxyandrostenedione*

262 *11KT: 11-ketotestosterone*

263 *T: Testosterone*

264

265

266 **Correlations between steroid measures**

267 In men, there was a strong positive correlation between 11KT with ACTH (0.845; $p < 0.001$),
 268 androstenedione ($R = 0.933$; $p < 0.001$), 17-OHP ($R = 0.942$; $p < 0.001$) and the
 269 androstenedione/testosterone (A/T)-ratio ($R = 0.837$; $p < 0.001$). A negative correlation of 11KT with
 270 testosterone was only seen on a trend level ($R = -0.278$; $p = 0.087$) and there was no significant

271 correlation with the free androgen index (FAI). 11OHA4 correlated positively with ACTH ($R = 0.868$; p
272 < 0.001), androstenedione (0.944 ; $p < 0.001$), 17-OHP ($R = 0.947$; $p < 0.001$) and the A/T-ratio ($R =$
273 0.857 ; $p < 0.001$). 11KT and 11OHA4 also were strongly correlated ($R = 0.976$; $p < 0.001$).

274 In women, there was a positive correlation of 11KT with ACTH ($R = 0.552$; $p < 0.001$), total
275 testosterone ($R = 0.899$; $p < 0.001$), androstenedione ($R = 0.889$; $p < 0.001$), 17-OHP ($R = 0.915$; $p <$
276 0.001), DHEAS ($R = 0.618$; $p < 0.001$) and the FAI ($R = 0.780$; $p < 0.001$). 11OHA4 correlated
277 positively with ACTH ($R = 0.604$; $p < 0.001$), total testosterone ($R = 0.875$; $p < 0.001$),
278 androstenedione ($R = 0.886$; $p < 0.001$), 17-OHP ($R = 0.915$; $p < 0.001$), DHEAS ($R = 0.637$; $p <$
279 0.001) and the FAI ($R = 0.781$; $p < 0.001$). The correlation between 11KT and 11OHA4 was weaker
280 than in men ($R = 0.477$; $p < 0.001$).

281 **Presence of TART**

282 There were no significant differences in steroid measures between those with and without TART.
283 There was also no difference in ACTH or gonadotropin levels, HC equivalence dosage or SV vs. SW
284 (data not shown).

285 **Hypogonadism in men**

286 Androstenedione levels were significantly higher in men with secondary hypogonadism than in those
287 with eugonadism ($4.5x$; $p = 0.023$). A similar pattern could be observed with 17-OHP ($14.4x$; $p =$
288 0.007), 11KT ($3.5x$; $p = 0.020$), 11OHA4 ($5.7x$, $p = 0.009$) and ACTH ($9.3x$; $p = 0.004$) (Figure 1).

289

290

291

292

293

294


295

296

297

298

299 **Figure 1 Differences between men with hypogonadism and eugonadism**



300

301 **Fig 1** Androstenedione levels were significantly higher in men with secondary hypogonadism than in
302 those with eugonadism (4.5x; $p = 0.023$). Same was true for 17-OHP (14.4x; $p = 0.007$), 11KT (3.5x; p
303 $= 0.020$), 11OHA4 (5.7x, $p = 0.009$) and ACTH (9.3x; $p = 0.004$). (Boxes represent the first to the third
304 quartile, vertical line indicates medians, crosses indicate outliers).

305

306 LH/FSH in men

307 In men, according to partial correlation analysis, adjusted for BMI and age, there was no significant
308 correlation of LH with any steroid measure. There was also no correlation with HC equivalence
309 dosage, type of GC (HC = 0 vs. synthetic GC = 1) or with regard to SV vs. SW.

310 In contrast, there were comparably strong negative correlations of androstenedione ($R = -0.330$; $p =$
311 0.048), 17-OHP ($R = -0.329$; $p = 0.047$); 11KT ($R = -0.368$; $p = 0.025$), 11OHA4 ($R = -0.361$; $p =$
312 0.028), the A/T-ratio ($R = -0.387$; $p = 0.018$) as well as the KT/T-ratio ($R = -0.383$; $p = 0.019$) with FSH.

313 There was no significant correlation with LH or FSH when adding KT+T as a new variable, given then
314 idea that both androgens should have equimolar androgenic potency according to the literature.

315 **Predictors of hypogonadism in men**

316 The only significant predictor for hypogonadism in men were elevated 17-OHP levels (B = 0.006; p =
317 0.039) in a stepwise logistic regression (0 = Eugonadism, 1= hypogonadism), including age, BMI,
318 ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 11OHA4. As expected, finding also remained
319 significant when adding HC-equivalence dosage as well as HC (0) vs GC (1) to the model (Table 3).

320 **Table 3 Stepwise regression of potential predictors of hypogonadism in men**

Variable	B	S.E.	p	Exp(B)	95% C.I.	
					Lower	Upper
Age*	-.037	.048	.435	.963	0.877	1.058
BMI*	-.004	.105	.966	.996	0.811	1.222
17-OHP	.006	.003	.039	1.006	1.000	1.011

321 **Forced entry including ACTH, androstenedione, 17-OHP, DHEAS, 11KT and 11OHA4 as independent*
322 *variables.*

323 *All variables were mean-centered. C.I. confidence interval*

324

325 **Amenorrhea in women**

326 ACTH (4.3x; p = 0.003), androstenedione (2.5x; p = 0.019), 17-OHP (8.1x; p = 0.002), 11KT (5.2x; p =
327 0.002), 11OHA4 (3.7x; p = 0.023) and testosterone (3.1x; p = 0.007) were significantly higher in
328 women with amenorrhea versus regular cycling women (Figure 2).

329

330

331

332

333

334

335


336

337

338

339
340
341
342

Figure 2 Differences between regular cycling and amenorrhoeic women



343
344
345
346
347
348
349

Fig 2 ACTH (4.3x; $p = 0.003$), androstenedione (2.5x; $p = 0.019$), 17-OHP (8.1x; $p = 0.002$), 11KT (5.2x; $p = 0.002$), 11OHA4 (3.7x; $p = 0.023$) and testosterone (3.1x; $p = 0.007$) were significantly higher in women with amenorrhoea in comparison to those with a regular cycle. (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate outliers).

350 Equivalence dosage of HC was lower (12.7mg/m² vs 16.4mg/m²; $p = 0.019$). There was no difference
351 in terms of GC vs HC use or HOMA-IR. There was also no difference in DHEAS levels and the A/T-
352 ratio. There was no significant difference in these parameters between those with irregular and those
353 with a regular cycle (data not shown).

354 Oral contraceptive use


355 Androstenedione ($p = 0.011$), the FAI ($p = 0.001$) and DHEAS ($p = 0.049$) were significantly lower in
356 women with a regular menstrual cycle in comparison to women currently taking an oral contraceptive
357 pill, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4 (Figure 3).

358

359

360 **Figure 3 Oral contraception vs regular cycle**

361



362

363 **Fig 3** When comparing those with a regular menstrual cycle with those currently taking an oral
364 contraceptive pill, androstenedione ($p = 0.011$), the FAI ($p = 0.001$) and DHEAS ($p = 0.049$) were
365 significantly lower, while there was no difference in total testosterone, 17-OHP, 11KT or 11OHA4.).
366 (Boxes represent the first to the third quartile, vertical line indicates medians, crosses indicate
367 outliers).

368

369 Predictors of amenorrhea

370 Only higher testosterone levels were significantly associated with amenorrhea ($B = 1.806$; $p = 0.040$)
371 in a logistic regression analysis including age, BMI (Enter) (0 = amenorrhea, 1= regular cycle), ACTH,
372 androstenedione, 17-OHP, DHEAS, total testosterone, free testosterone, the A/T-ratio, 11KT,
373 11OHA4, and the T/KT-ratio (stepwise) (Table 4).

374

375

376

377

378 **Table 4 Stepwise regression of potential predictors of amenorrhea**

Variable	B	S.E.	p	Exp(B)	95% C.I.	
					Lower	Upper
Age*	-0.097	0.111	0.381	.908	0.731	1.127
BMI*	-0.024	0.095	0.804	.977	0.812	1.176
Testosterone	1.806	0.877	0.040	6.085	1.091	33.955
Constant	0.796	0.803	0.321	2.216		

379 **Forced entry; Stepwise including ACTH, androstenedione, 17-OHP, DHEAS, total testosterone, free*
380 *testosterone, the A/T-ratio, 11KT, 11OHA4, and the T/KT-ratio as independent variables. All variables*
381 *were mean-centered. C.I. confidence interval.*

382

383 4. Discussion

384 We could demonstrate in this relatively large cohort that 11-oxygenated androgens are significantly
385 elevated in patients of both sexes with HPG-axis disturbances. They however do not seem to be the
386 most relevant androgens in this context.

387 The prevalence of hypogonadism in men and menstrual irregularities in women in our cohort was
388 comparable to that reported in the literature (7,24) and hence emphasizes that HPG-axis disturbances
389 are still a fairly common issue in this patient population. Despite a significant elevation of 11KT and
390 11OHA4, being in accordance with earlier studies (16), 17-OHP was a better predictor of
391 hypogonadism in male patients. Our data therefore do not indicate a leading role of 11KT in HPG-axis
392 suppression. This may be due to the fact that 11KT cannot be converted into estrogenic steroids and
393 many effects that had originally been attributed to testosterone in men are actually mediated via
394 aromatization to estradiol (25). This also includes sex steroid regulation at the hypothalamus/pituitary
395 level (19).

396 The significant role of 17OHP may be explained by the fact that progesterone is also a very potent
397 suppressor of the HPG-axis in men (26,27). As 17-OHP is a direct metabolite of progesterone, it is a

398 potent agonist of the PR (28) as also indicated by a strong positive correlation between both steroids
399 in patients with CAH (29).

400 In contrast to previous work (16) and our initial hypothesis, neither 11KT nor 11OHA4 were elevated in
401 men with TART and most steroid measures, including 11KT and 11OHA4 showed a negative instead
402 of a positive correlation with FSH as a potential marker of gonadal damage. Although our cohort was
403 age-wise comparable to those adult patients reported by Turcu et al., a considerable proportion of their
404 patients with TART were children. While TARTs in younger patients might still respond to HPA-axis
405 suppression, they seem to become less modifiable in the long-term due to fibrotic modifications (30).
406 In line, presence of TART has been associated with poor treatment quality in some (8) but not all
407 studies (9,31). Despite the factor of age, we cannot exclude that there were further differences in non-
408 recorded potential confounders such as long-term disease control distinguishing our patient groups.

409 11KT and 11OHA4 levels were also higher in women with secondary amenorrhea than in those with a
410 regular cycle, as having been reported before (16). But again, when adding other markers of disease
411 control to our model, testosterone was superior in explaining amenorrhea. Correspondingly, menstrual
412 cycle disturbances in female patients with CAH have been associated with poor androgen control (6).
413 Testosterone modulates GnRH-pulse frequency and therefore interferes with the complex hormonal
414 interplay during the menstrual cycle (32). In addition, it also has direct effects on the endometrium
415 (33).

416 Of note, there were no significant differences in 11KT or 11OHA4 between those with a regular cycle
417 and those currently taking hormonal contraceptives. This may be due to a lower binding affinity for
418 SHBG that has been suggested but not yet demonstrated for these steroids. This could be of clinical
419 relevance, as this might explain why some patients benefit less from oral contraceptive treatment with
420 regard to hyperandrogenic symptoms such as hirsutism and acne (34). However, prospective studies
421 are needed to substantiate this finding.

422 There are several limitations of our study. Firstly, due to the cross-sectional design we can only show
423 associations and no causality between dependent and independent variables. Prospective studies
424 with modifying interventions are therefore needed. A further limitation in this context is that, in contrast
425 to the general recommendation, the definition on hypogonadism in our study was based on a single,
426 instead of two testosterone measures in the morning (21). However, diurnal variance of testosterone

427 and LH in CAH do generally differ from the general male population due to the extra-gonadal
428 androgen production and also depend on GC pharmacokinetics (1). A further limitation of our study is
429 that we only used a single steroid measurement in the morning for our analyses. Steroid
430 measurements from blood drawn before the intake of the morning GC dosage might therefore yield
431 other results. However, all patients included were either receiving a morning dosage of HC or
432 prednisolone or an evening dosage of dexamethasone which show, given the wide inter-individual
433 variability, a comparable suppression profile for the chosen time window (35,36).

434 Lastly, although we investigated a large group of adult patients with classic CAH, given the rarity of
435 the disease, subgroups were rather small, stepwise regression had to be used for our final models.
436 Nonetheless, given the strong differences in steroid markers between groups we consider our results
437 to be valid.

438 **5. Conclusion**

439 In the present study, 11KT and 11OHA4 did not seem to add additional information to the
440 understanding of HPG-axis disturbances in CAH. Further studies have to show if 11oxC19 steroids are
441 of relevance for explaining for other health issues in CAH. It might be of particular interest, if they
442 could be a superior biomarker of disease control. To our knowledge it has not yet been shown to what
443 extent 11-oxygenated androgens show a diurnal variation, potentially addressing the still problematic
444 issue of timing of blood sampling with regard to different GC treatment regimens. Former approaches
445 to overcome these restrictions like serial salivary (36) or blood sampling (37), or hair steroid measures
446 (52) are on the one hand very time consuming and on the other hand have so far not yet been proven
447 to be superior in terms of predicting clinically relevant long-term outcomes. Lastly, it would have to be
448 demonstrated that 11KT can be independently targeted by treatment-modification, independent of
449 other adrenal androgens.

450

451

452

453

454

455

456

457

458 6. References

459

- 460 1. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL,
461 Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid
462 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. *J Clin*
463 *Endocrinol Metab.* 2018;103(11):4043-4088.
- 464 2. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
465 *Endocrine reviews.* 2000;21(3):245-291.
- 466 3. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke
467 DP. 11-Oxygenated Androgens Are Biomarkers of Adrenal Volume and Testicular Adrenal
468 Rest Tumors in 21-Hydroxylase Deficiency. *The Journal of clinical endocrinology and*
469 *metabolism.* 2017;102(8):2701-2710.
- 470 4. Stikkelbroeck NM, Sweep CF, Braat DD, Hermus AR, Otten BJ. Monitoring of menstrual
471 cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-
472 hydroxylase deficiency. *Fertility and sterility.* 2003;80(4):1030-1036.
- 473 5. RICHARDS GE, GRUMBACH MM, KAPLAN SL, CONTE FA. The Effect of Long Acting
474 Glucocorticoids on Menstrual Abnormalities in Patients with Virilizing Congenital Adrenal
475 Hyperplasia*. *The Journal of Clinical Endocrinology & Metabolism.* 1978;47(6):1208-1215.
- 476 6. Bachelot A, Chakhtoura Z, Plu-Bureau G, Coudert M, Coussieu C, Badachi Y, Dulon J,
477 Charbit B, Touraine P, Group CS. Influence of hormonal control on LH pulsatility and secretion
478 in women with classical congenital adrenal hyperplasia. *European journal of endocrinology.*
479 2012;167(4):499.
- 480 7. Engels M, Gehrman K, Falhammar H, Webb EA, Nordenstrom A, Sweep F, Span PN, van
481 Herwaarden AE, Rohayem J, Richter-Unruh A. Gonadal function in adult male patients with
482 congenital adrenal hyperplasia. *European journal of endocrinology.* 2018;EJE-17-0862.
- 483 8. King TF, Lee MC, Williamson EE, Conway GS. Experience in optimizing fertility outcomes in
484 men with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. *Clinical*
485 *endocrinology.* 2016;84(6):830-836.
- 486 9. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, Wolff H,
487 Schwarz H-P, Quinkler M, Beuschlein F. High prevalence of reduced fecundity in men with
488 congenital adrenal hyperplasia. *The Journal of Clinical Endocrinology & Metabolism.*
489 2009;94(5):1665-1670.
- 490 10. Richards G, Grumbach M, Kaplan S, Conte F. The effect of long acting glucocorticoids on
491 menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. *The Journal*
492 *of Clinical Endocrinology & Metabolism.* 1978;47(6):1208-1215.
- 493 11. Kaprara A, Huhtaniemi IT. The hypothalamus-pituitary-gonad axis: tales of mice and men.
494 *Metabolism.* 2018;86(3-17).
- 495 12. Turcu AF, Rege J, Auchus RJ, Rainey WE. 11-Oxygenated androgens in health and disease.
496 *Nature Reviews Endocrinology.* 2020;1-13.
- 497 13. Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. *Current opinion in*
498 *endocrinology, diabetes, and obesity.* 2017;24(3):252.
- 499 14. Imamichi Y, Yuhki K-i, Orisaka M, Kitano T, Mukai K, Ushikubi F, Taniguchi T, Umezawa A,
500 Miyamoto K, Yazawa T. 11-ketotestosterone is a major androgen produced in human gonads.
501 *The Journal of Clinical Endocrinology & Metabolism.* 2016;101(10):3582-3591.
- 502 15. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey
503 WE, Auchus RJ. Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant

- 504 androgens in classic 21-hydroxylase deficiency. *European journal of endocrinology*.
505 2016;174(5):601-609.
- 506 16. Turcu AF, Mallappa A, Elman MS, Avila NA, Marko J, Rao H, Tsodikov A, Auchus RJ, Merke
507 DP. 11-Oxygenated androgens are biomarkers of adrenal volume and testicular adrenal rest
508 tumors in 21-hydroxylase deficiency. *The Journal of Clinical Endocrinology & Metabolism*.
509 2017;102(8):2701-2710.
- 510 17. Resko JA, Ellinwood WE. Negative feedback regulation of gonadotropin secretion by
511 androgens in fetal rhesus macaques. *Biology of reproduction*. 1985;33(2):346-352.
- 512 18. KEENAN BS, EBERLE AJ, SPARROW JT, GREGER NG, PANKO WB. Dihydrotestosterone
513 heptanoate: synthesis, pharmacokinetics, and effects on hypothalamic-pituitary-testicular
514 function. *The Journal of Clinical Endocrinology & Metabolism*. 1987;64(3):557-562.
- 515 19. Raven G, de Jong FH, Kaufman J-M, de Ronde W. In men, peripheral estradiol levels directly
516 reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin
517 secretion. *The Journal of Clinical Endocrinology & Metabolism*. 2006;91(9):3324-3328.
- 518 20. Hawley JM, Adaway JE, Owen LJ, Keevil BG. Development of a total serum testosterone,
519 androstenedione, 17-hydroxyprogesterone, 11 β -hydroxyandrostenedione and 11-
520 ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical sample
521 stability. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2020;58(5):741-752.
- 522 21. Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. *Advances*
523 *in the management of testosterone deficiency*. Vol 37: Karger Publishers; 2009:5-20.
- 524 22. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. *American family*
525 *physician*. 2006;73(8):1374-1382.
- 526 23. Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-
527 hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients
528 from southern Germany. *The Journal of Clinical Endocrinology & Metabolism*.
529 2000;85(3):1059-1065.
- 530 24. Reichman DE, White PC, New MI, Rosenwaks Z. Fertility in patients with congenital adrenal
531 hyperplasia. *Fertility and sterility*. 2014;101(2):301-309.
- 532 25. Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF, Jones BF, Barry
533 CV, Wulczyn KE, Thomas BJ. Gonadal steroids and body composition, strength, and sexual
534 function in men. *New England Journal of Medicine*. 2013;369(11):1011-1022.
- 535 26. Auer MK, Fuss J, Stalla GK, Athanasoulia AP. Twenty years of endocrinologic treatment in
536 transsexualism: analyzing the role of chromosomal analysis and hormonal profiling in the
537 diagnostic work-up. *Fertility and sterility*. 2013;100(4):1103-1110.
- 538 27. Fuss J, Claro L, Ising M, Biedermann SV, Wiedemann K, Stalla GK, Briken P, Auer MK. Does
539 sex hormone treatment reverse the sex-dependent stress regulation? A longitudinal study on
540 hypothalamus-pituitary-adrenal (HPA) axis activity in transgender individuals.
541 *Psychoneuroendocrinology*. 2019;104(228-237).
- 542 28. Attardi BJ, Zeleznik A, Simhan H, Chiao JP, Mattison DR, Caritis SN, Network OFPRU.
543 Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene
544 expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.
545 *American journal of obstetrics and gynecology*. 2007;197(6):599. e591-599. e597.
- 546 29. HUGHES IA, WINTER JS. The relationships between serum concentrations of 17OH-
547 progesterone and other serum and urinary steroids in patients with congenital adrenal
548 hyperplasia. *The Journal of Clinical Endocrinology & Metabolism*. 1978;46(1):98-104.
- 549 30. Claahsen-Van der Grinten H, Otten B, Stikkelbroeck M, Sweep F, Hermus A. Testicular
550 adrenal rest tumours in congenital adrenal hyperplasia. *Best practice & research Clinical*
551 *endocrinology & metabolism*. 2009;23(2):209-220.
- 552 31. Reisch N, Scherr M, Flade L, Bidlingmaier M, Schwarz H-P, Muller-Lisse U, Reincke M,
553 Quinkler M, Beuschlein F. Total adrenal volume but not testicular adrenal rest tumor volume is
554 associated with hormonal control in patients with 21-hydroxylase deficiency. *The Journal of*
555 *Clinical Endocrinology & Metabolism*. 2010;95(5):2065-2072.
- 556 32. Melrose P, Gross L. Steroid effects on the secretory modalities of gonadotropin-releasing
557 hormone release. *Endocrinology*. 1987;121(1):190-199.
- 558 33. Rose GL, Dowsett M, Mudge JE, White JO, Jeffcoate SL. The inhibitory effects of danazol,
559 danazol metabolites, gestrinone, and testosterone on the growth of human endometrial cells in
560 vitro. *Fertility and sterility*. 1988;49(2):224-228.
- 561 34. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, Shapiro J, Montori
562 VM, Swiglo BA. Evaluation and treatment of hirsutism in premenopausal women: an endocrine
563 society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*.
564 2008;93(4):1105-1120.

- 565 **35.** Charmandari E, Matthews DR, Johnston A, Brook CG, Hindmarsh PC. Serum cortisol and 17-
566 hydroxyprogesterone interrelation in classic 21-hydroxylase deficiency: is current replacement
567 therapy satisfactory? *The Journal of Clinical Endocrinology & Metabolism*. 2001;86(10):4679-
568 4685.
- 569 **36.** Großschl M, Rauh M, Dörr HG. Cortisol and 17-hydroxyprogesterone kinetics in saliva after
570 oral administration of hydrocortisone in children and young adolescents with congenital
571 adrenal hyperplasia due to 21-hydroxylase deficiency. *The Journal of Clinical Endocrinology &*
572 *Metabolism*. 2002;87(3):1200-1204.
- 573 **37.** Young M, Walker R, Riad-Fahmy D, Hughes I. Androstenedione rhythms in saliva in
574 congenital adrenal hyperplasia. *Archives of disease in childhood*. 1988;63(6):624-628.
- 575